PRAX

303.6502.33%
DJ

Dean Jonathan Mitchell

Independent Chairman of the Board

Mr. Dean Jonathan Mitchell was Lead Independent Director of Theravance Biopharma Us, Inc. from June 2014 until September 23, 2026. Mr. Mitchell served as Chairman of the Board at ReCode Therapeutics, Inc. from May 2024. He served as Lead Independent Director at Theravance Biopharma, Inc. since July 2023 until October 2024. He served as Independent Chair of Kinnate Biopharma Inc. from August 2020 to April 3, 2024. Mr. Mitchell served as an Independent Director of Kinnate Biopharma Inc. from August 2020 to April 3, 2024. Mr. Mitchell serves as an Independent Chairman of the Board at Praxis Precision Medicines, Inc. since September 17, 2020 and has been its Independent Director since August 2020. He served as an Executive Chairman of the Board of Covis Pharma Holdings S.à r.l. from July 2013 until its sale in March 2020 and was Chairman of PaxVax Corporation from October 2016 until its sale in October 2018. He was Chairman of Covid Pharma Holdings. Mr. Mitchell served as an Executive Officer of MGI Pharma, Inc. since October 2005. He served as the Chief Executive Officer and President of Lux Biosciences, Inc. from July 2010 to August 2013. He served as Chief Executive Officer and President at Zoetis Products LLC from July 2006 to December 2008. He served as the President and Chief Executive Officer of Alpharma Inc. from July 1, 2006, to December 2008. Mr. Mitchell served as Vice President of Strategy of Bristol-Myers Squibb (BMS) from February 2004 to November 2004. He served as the President and Chief Executive Officer of Guilford Pharmaceuticals Inc. from December 1, 2004, to October 2005. He served as an Executive Director of Alpharma, Inc. from July 1, 2006, to December 2008. From September 2001 to February 2002, he served as the President, International, Worldwide Medicines Pharmaceuticals Group, a division of Bristol-Myers Squibb. He served at Bristol Myers Squibb from 2001 to 2004 in several roles. Prior to BMS, he spent 14 years at GlaxoSmithKline PLC. From June 1995 to September 1999, Mr. Mitchell served as a Vice President and General Manager of Specialty Divisions, Strategic Planning and Business Development of Glaxo Wellcome PLC. From September 1999 to August 2001, he served as Senior Vice President of Clinical Development and Product Strategy at GlaxoSmithKline PLC. He had been an Independent Director of ImmunoGen, Inc. since 2012, until February 12, 2024. Mr. Mitchell has been an Independent Director at Theravance Biopharma, Inc. since June 2, 2014. Mr. Mitchell was an Independent Director of Precigen, Inc. (formerly, Intrexon Corporation) since March 2009 until July 5, 2024. He served as Director of Lux Biosciences, Inc. He served as a Director of Talecris Biotherapeutics Holdings Corp. until June 1, 2011. He served as an Independent Director of ISTA Pharmaceuticals, Inc. since July 2004. He served as Director at Zoetis Products LLC from July 2006 to December 2008. He served as a Director of MGI Pharma, Inc. from October 2005 to January 2008. Mr. Mitchell served as a Director of Guilford Pharmaceuticals Inc. since December 1, 2004, until its acquisition by MGI Pharma Inc. in 2005. He is a Treasurer of the National Pharmaceutical Council. He was Vice Chairman of the National Pharmaceutical Council and serves on its Board. Mr. Mitchell holds a B.S. in Applied Biology from Coventry University and an M.B.A. from City University London.

Positions